News

Nov 23, 2020

By sarahjibrin

HiFiBiO Therapeutics Inks Partnership with Pharmsynthez and IBCh for the Clinical Development and Commercialization of its SARS-CoV-2 Neutralizing Antibody in Russia

Oct 27, 2020

By sarahjibrin

HiFiBiO Therapeutics CEO Liang Schweizer Named one of the World’s Top Female Founders

Oct 26, 2020

By sarahjibrin

HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19

Sep 24, 2020

By sarahjibrin

HiFiBiO Therapeutics CEO Liang Schweizer Receives 2020 Extraordinary Women Advancing Healthcare Award

Sep 17, 2020

By sarahjibrin

HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS™ Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference

Sep 3, 2020

By sarahjibrin

KITE AND HIFIBIO THERAPEUTICS PARTNER TO DISCOVER NOVEL TARGETS AND ANTIBODIES AGAINST ACUTE MYELOID LEUKEMIA

Aug 26, 2020

By sarahjibrin

HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients

Aug 17, 2020

By sarahjibrin

HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19

Jul 3, 2020

By sarahjibrin

HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment

Jul 3, 2020

By sarahjibrin

Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment